🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Pfizer Inc (PFE)

NYSE
Currency in USD
26.10
+0.37(+1.44%)
Closed
Pre Market
26.19+0.09(+0.34%)
PFE Scorecard
Full Analysis
Has raised its dividend for 14 consecutive years
High dividend Yield
Fair Value
Day's Range
25.5826.44
52 wk Range
24.4831.54
Key Statistics
Edit
Prev. Close
26.1
Open
25.76
Day's Range
25.58-26.44
52 wk Range
24.48-31.54
Volume
37.46M
Average Vol. (3m)
38.97M
1-Year Change
-9.31%
Book Value / Share
16.29
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PFE Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
32.60
Upside
+24.90%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Pfizer Inc Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Employees
88000

Pfizer Inc SWOT Analysis


Analyst Perspectives
Average price target around $35, with ratings ranging from Hold to Overweight, reflecting varied views on Pfizer's post-COVID growth potential
Pipeline Promise
Delve into Pfizer's robust pipeline, focusing on oncology and vaccines, with potential blockbusters and the strategic Seagen integration
Strategic Pivot
Explore Pfizer's multi-pronged approach to address patent cliff concerns, including cost-cutting measures aiming for $4B in net savings by 2024
Financial Resilience
Pfizer surpasses Q2 expectations with $13.28B revenue, raising 2024 guidance to $59.5B-$62.5B sales and $2.45-$2.65 adjusted EPS
Read full SWOT analysis
PFE Full Pro Research
Institutional-Grade Stock Analysis
Understand how PFE earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks

Pfizer Inc Earnings Call Summary for Q3/2024

  • Pfizer reports first YoY revenue growth since Q4 2022, reaching 192M+ patients in H1 2024
  • Company raises full-year revenue and earnings guidance for 2024, signaling optimism
  • Focus on oncology leadership, pipeline innovation, and shareholder value; Seagen integration progressing
  • Cost-realignment and manufacturing optimization expected to save $1.5B+ by 2027
  • Confident in navigating IRA impact; core business strong with key products showing notable performance
Last Updated: 07/30/2024, 05:23 PM
Read Full Transcript

Compare PFE to Peers and Sector

Metrics to compare
PFE
Peers
Sector
Relationship
P/E Ratio
34.6x−1.4x−0.6x
PEG Ratio
−0.580.040.00
Price / Book
1.6x2.4x2.6x
Price / LTM Sales
2.5x2.8x3.2x
Upside (Analyst Target)
22.6%768.7%46.2%
Fair Value Upside
Unlock−2.1%7.0%Unlock

Analysts' Recommendations

11 Buy
13 Hold
1 Sell
Ratings:
23 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 32.60

(+24.91% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.751
Dividend Yield
6.53%
Industry Median 1.74%
Annualized Payout
1.6800
Paid quarterly
5-Years Growth
+3.30%
Growth Streak

People Also Watch

72.46
PLTR
-5.08%
138.81
NVDA
-2.55%
308.30
V
-0.87%
243.81
JPM
-1.44%
112.90
XOM
-0.59%

FAQ

What Is the Pfizer (PFE) Stock Price Today?

The Pfizer stock price today is 26.10

What Stock Exchange Does Pfizer Trade On?

Pfizer is listed and trades on the NYSE stock exchange.

What Is the Stock Symbol for Pfizer?

The stock symbol for Pfizer is "PFE."

Does Pfizer Pay Dividends? What’s The Current Dividend Yield?

The Pfizer dividend yield is 6.44%.

What Is the Pfizer Market Cap?

As of today, Pfizer market cap is 147.91B.

What is Pfizer Earnings Per Share?

The Pfizer EPS is 0.751.

What Is the Next Pfizer Earnings Date?

Pfizer will release its next earnings report on Feb 04, 2025.

From a Technical Analysis Perspective, Is PFE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.